<table>
<thead>
<tr>
<th>Trial Title</th>
<th>Description</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Contact Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYSTEMS-2: A Randomised Phase II trial of standard of care chemotherapy vs Nintedanib Monotherapy Versus Placebo in Combination with Pembrolizumab for the Treatment of Symptomatic Malignant Pleural Mesothelioma</td>
<td>The pilot component will develop the symptom questionnaire and use ASyMS-meso for a period of 3 months. ASyMS-meso will collect quality of life data and ASyMS-meso will be used to explore the symptom burden. Also, by contacting Mr Eric Lim, or Dr Naomi Klepacz, will be able to find out more about the study.</td>
<td>Professor Dean Fennell, Professor Anthony Chalmers</td>
<td>Beatson Cancer Trust Co-ordination and Development Team</td>
<td><a href="mailto:len.darling@beatson.org">len.darling@beatson.org</a>, <a href="mailto:Laura.alexander@glasgow.ac.uk">Laura.alexander@glasgow.ac.uk</a>, <a href="mailto:jean.hutson@glasgow.ac.uk">jean.hutson@glasgow.ac.uk</a></td>
</tr>
<tr>
<td>Continued Nintedanib Monotherapy Versus Placebo in Combination with Pembrolizumab for the Treatment of Symptomatic Malignant Pleural Mesothelioma</td>
<td>A feasibility study to demonstrate the best treatment for managing symptoms of malignant pleural mesothelioma.</td>
<td>Professor Dean Fennell, Professor Anthony Chalmers</td>
<td>Beatson Cancer Trust Co-ordination and Development Team</td>
<td><a href="mailto:len.darling@beatson.org">len.darling@beatson.org</a>, <a href="mailto:Laura.alexander@glasgow.ac.uk">Laura.alexander@glasgow.ac.uk</a>, <a href="mailto:jean.hutson@glasgow.ac.uk">jean.hutson@glasgow.ac.uk</a></td>
</tr>
<tr>
<td>Placebo + Pemetrexed / Cisplatin Followed by Placebo for the Treatment of Malignant Pleural Mesothelioma</td>
<td>A study to determine whether it can improve outcomes in treatment for the first time. Following a screening period, patients will be randomised to receive either experimental or control arm.</td>
<td>Professor Dean Fennell, Professor Anthony Chalmers</td>
<td>Beatson Cancer Trust Co-ordination and Development Team</td>
<td><a href="mailto:len.darling@beatson.org">len.darling@beatson.org</a>, <a href="mailto:Laura.alexander@glasgow.ac.uk">Laura.alexander@glasgow.ac.uk</a>, <a href="mailto:jean.hutson@glasgow.ac.uk">jean.hutson@glasgow.ac.uk</a></td>
</tr>
</tbody>
</table>

**Eligibility Criteria**

1. Able to provide informed consent
2. Trapped lung, defined as a “clinically apparent narrowing of the space between the parietal and visceral pleura.”
3. Symptomatic brain or spinal cord metastases and/or carcinomatous meningitis.
4. Major thoracic or abdominal surgery, e.g., VAT-PD plus pleurectomy/decortication, within 4 months of study entry AND no additional therapy is required during the study period.
5. Have provided a signed informed consent to the investigator, eyes, or study drug. 
6. Prior chemotherapy for pleural mesothelioma that has been disease-free for at least 3 years.
7. Prior thoracic radiotherapy (20Gy in 5 fractions delivered over 1 week).
8. Adequate hematologic, renal, or hepatic function.
9. No positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.
10. Not pregnant at study entry AND no additional therapy is required during the study period.
11. No history of severe hypersensitivity reactions to other monoclonal antibodies.
13. Have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
14. History of severe hypersensitivity reactions to other monoclonal antibodies.
15. Known acquired immunodeficiency syndrome (AIDS).